A mailing from Takeda's Millennium Pharmaceuticals Inc unit overstated Velcade's effectiveness and failed to contain the appropriate information about its approved uses and risks, the Food and Drug Administration said in a letter to the company.
Wednesday, June 24, 2009
Takeda - Velcade: slapped wrist
WASHINGTON, June 23 (Reuters) - U.S. regulators have warned a Takeda Pharmaceutical Co unit about a misleading promotion for cancer drug Velcade.
A mailing from Takeda's Millennium Pharmaceuticals Inc unit overstated Velcade's effectiveness and failed to contain the appropriate information about its approved uses and risks, the Food and Drug Administration said in a letter to the company.
A mailing from Takeda's Millennium Pharmaceuticals Inc unit overstated Velcade's effectiveness and failed to contain the appropriate information about its approved uses and risks, the Food and Drug Administration said in a letter to the company.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment